By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Coming soon
Red-orange chemical bilirubin (BR), sometimes known as “red bile,” is produced by the usual catabolic process used by vertebrates to break down heme. The body needs to go through this catabolism in order to get rid of waste products that result from the oxidation of old or dysfunctional red blood cells.
The heme molecule is separated from the hemoglobin molecule in the initial phase of the bilirubin production process. The steps of porphyrin catabolism that heme goes through next vary depending on the part of the body where the breakdown takes place. For instance, the chemicals expelled in pee and feces are different.
The first significant step in the catabolic process is the synthesis of biliverdin from heme, and the second step is carried out by the enzyme biliverdin reductase, which creates bilirubin from biliverdin.
Elevated amounts of bilirubin, which is ultimately broken down by the body and expelled as metabolites in the urine and bile, may signify certain disorders. It is in charge of both the yellow discoloration in jaundice and the color of healed injuries.
Its breakdown products, such as stercobilin, are what give feces their brown hue. Urobilin, a separate breakdown product, is what gives urine its straw-yellow hue.
Even though bilirubin is often only found in mammals, one plant species, Strelitzia Nicolai, has been shown to have the pigment.
A bilirubin analyzer is a tool for measuring bilirubin levels and is frequently used in neonatal intensive care units to check for jaundice in newborns. The analyzers either assess skin reflectance or measure bilirubin levels in blood or serum samples, which essentially removes the costs, discomfort, and time associated with blood draws.
The Global Bilirubin Analyzer market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.
Neonate bilirubin test results from the new OMNI S bilirubin analyzer are available in seconds.
It used to be virtually entirely the responsibility of the busy lab personnel who spend their days operating the huge clinical chemistry analyzers in a hospital’s high-volume central laboratory to screen and swiftly diagnose neonates with increased and dangerous levels of bilirubin.
Now that hospitals concentrating on critical care near patient testing continue to invest in the OMNI S analyzer, the most recent addition to the OMNI blood gas analyzer line produced and distributed by Roche Diagnostics, testing methodology is quickly evolving.
